I'm not sure how relevant this is, but there was an update from Replicel on Twitter today:
Brief update: we have data pouring in from 3 different programs testing our
@DermaPrecise with all kinds of injectables, materials, and specifications. This is helping us narrow down most ideal applications for market launch and FDA submissions.
We are nearly finished preparations on an Early Adopter Program for Key Opinion Leaders in three continents for pre-clinical and clinical evaluations in different applications.
@DermaPrecise
#dermalinjector #dermalinjection More details announced